Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA139551
Max Phase: Preclinical
Molecular Formula: C21H20N4O7
Molecular Weight: 440.41
Molecule Type: Small molecule
Associated Items:
ID: ALA139551
Max Phase: Preclinical
Molecular Formula: C21H20N4O7
Molecular Weight: 440.41
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Nc1nc(O)c2cc(COc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)ccc2n1
Standard InChI: InChI=1S/C21H20N4O7/c22-21-24-15-6-1-11(9-14(15)19(29)25-21)10-32-13-4-2-12(3-5-13)18(28)23-16(20(30)31)7-8-17(26)27/h1-6,9,16H,7-8,10H2,(H,23,28)(H,26,27)(H,30,31)(H3,22,24,25,29)
Standard InChI Key: MNMMLPGKBNWPGY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 440.41 | Molecular Weight (Monoisotopic): 440.1332 | AlogP: 1.54 | #Rotatable Bonds: 9 |
Polar Surface Area: 184.96 | Molecular Species: ACID | HBA: 8 | HBD: 5 |
#RO5 Violations: 0 | HBA (Lipinski): 11 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.04 | CX Basic pKa: 2.60 | CX LogP: 1.37 | CX LogD: -4.81 |
Aromatic Rings: 3 | Heavy Atoms: 32 | QED Weighted: 0.33 | Np Likeness Score: -0.50 |
1. Patil SA, Shane B, Freisheim JH, Singh SK, Hynes JB.. (1989) Inhibition of mammalian folylpolyglutamate synthetase and human dihydrofolate reductase by 5,8-dideaza analogues of folic acid and aminopterin bearing a terminal L-ornithine., 32 (7): [PMID:2738891] [10.1021/jm00127a026] |
2. Hynes JB, Patil SA, Tomazic A, Kumar A, Pathak A, Tan XH, Li XQ, Ratnam M, Delcamp TJ, Freisheim JH.. (1988) Inhibition of murine thymidylate synthase and human dihydrofolate reductase by 5,8-dideaza analogues of folic acid and aminopterin., 31 (2): [PMID:3339615] [10.1021/jm00397a031] |
3. Hynes JB, Patil SA, Hagan RL, Cole A, Kohler W, Freisheim JH.. (1989) Comparison of the biological effects of selected 5,8-dideazafolate analogues with their 2-desamino counterparts., 32 (4): [PMID:2704031] [10.1021/jm00124a019] |
4. Dayam R, Aiello F, Deng J, Wu Y, Garofalo A, Chen X, Neamati N.. (2006) Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents., 49 (15): [PMID:16854058] [10.1021/jm051296s] |
5. Chen BK, Horváth C, Bertino JR.. (1979) Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines., 22 (5): [PMID:110930] [10.1021/jm00191a005] |
Source(1):